Delay in supplying new screening device expected to hit sales
Tim Hunter Fri, 02 Oct 2015
Listed technology minnow Truscreen has warned supplies of its core cancer screening product won’t be available until the end of the year after running out of its original stock.
The company told shareholders at its annual meeting just a week ago it hoped to have its new stock of product certified
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).